ZYNE

Q: What is the price of Zynerba Pharmaceuticals (ZYNE) today?

The current price of Zynerba Pharmaceuticals (ZYNE) is $ 0.00, representing a 0% gain over the past year. The stock began the year trading around $ 0.00 and is currently priced at $ 0.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does Zynerba Pharmaceuticals (ZYNE) pay dividends?

Zynerba Pharmaceuticals (ZYNE) did not pay dividends over the past year.

Zynerba Pharmaceuticals Inc.

Price

$ -

return (12m)

0.00%

p/e

-1.17

p/bv

2.25

DIVIDEND YIELD

0.00%

ZYNE price

Zynerba Pharmaceuticals

If you had invested

exposure

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

15 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ZYNE

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals ZYNE

review the fundamentals of Zynerba Pharmaceuticals shares

P/E

-1.17

Sector: -1.73 Industry: 0.91

P/S (PSR)

Sector: 1.96 Industry: 2.47

P/BV

2.25

Sector: 2.10 Industry: 2.36

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

-138.17%

Sector: -27.52% Industry: -25.21%

ROE

-192.71%

Sector: -33.12% Industry: -32.97%

ROIC

Sector: -439.47% Industry: -94.66%

NET MARGIN

0.00%

Sector: -29.81% Industry: -31.02%

GROSS MARGIN

0.00%

Sector: 45.08% Industry: 49.89%

OPERATING MARGIN

0.00%

Sector: -24.71% Industry: -27.53%

EV/EBITDA

-1.16

Sector: -0.17 Industry: 1.04

EV/EBIT

-1.15

Sector: -1.73 Industry: -0.01

PRICE-TO-ASSETS

1.61

Sector: 1.15 Industry: 1.30

BVPS

0.58

Sector: 3.92 Industry: 5.25

EPS

-1.12

Sector: -0.89 Industry: -0.69

EQUITY-TO-ASSETS RATIO

0.72

Sector: 0.43 Industry: 0.46

LIABILITIES / ASSETS

0.72

Sector: 0.47 Industry: 0.51

CAGR REVENUE 5 YEARS

0.00%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

8.43%

Sector: - Industry: -

Fundamentals ZYNE

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
LLY	39.95	32.37	81.02%	0.55%	$ 1.01 T	34.99%
ISRG	50.29	8.51	16.93%	0.00%	$ 149.83 B	28.15%
SNY	7.36	1.31	17.79%	8.84%	$ 109.89 B	14.75%
TMO	25.68	3.38	13.15%	0.37%	$ 175.88 B	15.15%
NVS	21.04	7.31	34.77%	2.08%	$ 284.75 B	23.92%
ABT	23.76	2.83	11.91%	2.85%	$ 149.12 B	13.91%
MDT	22.71	2.13	9.38%	3.48%	$ 104.78 B	13.00%
GSK	13.10	4.42	33.77%	3.43%	$ 102.78 B	17.79%
CVS	41.65	1.57	3.78%	2.77%	$ 122.12 B	0.72%
BSX	20.36	2.81	13.78%	0.00%	$ 72.58 B	17.29%
TMDX	13.73	4.78	34.80%	0.00%	$ 2.36 B	27.04%
IDXX	41.06	28.90	70.38%	0.00%	$ 44.97 B	24.63%
HCA	12.27	-27.99	-228.14%	0.79%	$ 83.36 B	8.89%
RMD	18.65	4.37	23.41%	1.19%	$ 28.34 B	27.44%
DHR	35.37	2.46	6.97%	0.74%	$ 130.48 B	14.89%
INMD	9.78	1.29	13.18%	0.00%	$ 853.02 M	23.27%
PHG	22.01	1.88	8.56%	3.88%	$ 24.87 B	5.50%
SYK	34.98	5.08	14.52%	1.13%	$ 116.73 B	13.21%
CI	11.78	1.81	15.39%	2.10%	$ 76.49 B	2.34%

Stock vs Indice Comparison Tool

If you had invested

years ago

2 years

5 years

10 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ZYNE Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (0 people)

United States

19 years

Founded: 2007

2015

Time since IPO - 11 years

26

Employees

Zynerba Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $65.20 Millions, with shareholders equity totaling $29.02 Millions.

The company employs approximately 26 people and operates in the Health sector, within the Pharmaceutical Products industry.

Over the past 12 months, Zynerba Pharmaceuticals Inc. reported $- in revenue, generating net income of $-55.93 Millions.

Key financial metrics include a P/E ratio of -1.17, a price-to-book (P/B) ratio of 2.25, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ZYNE.

Market cap

$ 65.20 Millions

Net worth

$ 29.02 Millions

$ 29,020,570.00

Assets

$ 40.48 Millions

$ 40,476,561.00

Total Shares Outstanding

50.15 Millions

50,150,000

Average Daily Trading Volume

$ 1.29 Million

$ 1,292,942.12

Sector

Health

Industry

Pharmaceutical Products

ZYNE

ZYNE revenue and profits

Financial Results ZYNE

DRAG THE FRAME TO SEE MORE DATA

ZYNE cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

CVS - CVS Health

$ 101.96 56,65% (12M)

P/E

41.65

2.77%

ROE

3.78%

P/BV

1.57

CI - Cigna

$ 298.00 --3,58% (12M)

P/E

11.78

2.10%

ROE

15.39%

P/BV

1.81

CNC - Centene

$ 65.19 18,06% (12M)

P/E

-4.76

0.00%

ROE

-29.93%

P/BV

1.42

HUM - Humana

$ 379.22 64,15% (12M)

P/E

37.18

1.01%

ROE

6.06%

P/BV

2.25

SNY - Sanofi

$ 44.25 --7,40% (12M)

P/E

7.36

8.84%

ROE

17.79%

P/BV

1.31

LLY - Eli Lilly

$ 1,133.00 41,29% (12M)

P/E

39.95

0.55%

ROE

81.02%

P/BV

32.37

HCA - HCA Healthcare

$ 387.18 5,20% (12M)

P/E

12.27

0.79%

ROE

-228.14%

P/BV

-27.99

NVS - Novartis

$ 153.07 30,64% (12M)

P/E

21.04

2.08%

ROE

34.77%

P/BV

7.31

CVS - CVS Health

$ 101.96 56,65% (12 M)

P/L

41.65

2.77%

ROE

3.78%

P/VP

1.57

CI - Cigna

$ 298.00 --3,58% (12 M)

P/L

11.78

2.10%

ROE

15.39%

P/VP

1.81

CNC - Centene

$ 65.19 18,06% (12 M)

P/L

-4.76

0.00%

ROE

-29.93%

P/VP

1.42

HUM - Humana

$ 379.22 64,15% (12 M)

P/L

37.18

1.01%

ROE

6.06%

P/VP

2.25

SNY - Sanofi

$ 44.25 --7,40% (12 M)

P/L

7.36

8.84%

ROE

17.79%

P/VP

1.31

LLY - Eli Lilly

$ 1,133.00 41,29% (12 M)

P/L

39.95

0.55%

ROE

81.02%

P/VP

32.37

HCA - HCA Healthcare

$ 387.18 5,20% (12 M)

P/L

12.27

0.79%

ROE

-228.14%

P/VP

-27.99

NVS - Novartis

$ 153.07 30,64% (12 M)

P/L

21.04

2.08%

ROE

34.77%

P/VP

7.31

Frequently Asked Questions

What is the price of Zynerba Pharmaceuticals (ZYNE) today?

The current price of Zynerba Pharmaceuticals (ZYNE) is $ 0.00, representing a 0% gain over the past year. The stock began the year trading around $ 0.00 and is currently priced at $ 0.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Zynerba Pharmaceuticals (ZYNE) pay dividends?

Zynerba Pharmaceuticals (ZYNE) did not pay dividends over the past year.

Is Zynerba Pharmaceuticals (ZYNE) a good investment?

Zynerba Pharmaceuticals (ZYNE) is currently trading at $ 0.00 with a P/E ratio of -1.17. This represents a -80% premium compared to its historical average P/E. Over the past year, the stock has gained 0 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Zynerba Pharmaceuticals (ZYNE) stock?

You can buy Zynerba Pharmaceuticals (ZYNE) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol ZYNE and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Zynerba Pharmaceuticals (ZYNE) yield today?

Over the past month, Zynerba Pharmaceuticals (ZYNE) has returned 0.00% — 0.00% over the past year, and 0.00% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Zynerba Pharmaceuticals (ZYNE) today at the current price of $ 0.00 your total investment would be $ 0.00.

Based on historical performance, the investment would have grown to approximately:

$ 0.00 after 1 year
$ 0.00 after 5 years
$ 0.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ZYNE

Zynerba Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ZYNE

review the fundamentals of Zynerba Pharmaceuticals shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Inc.

United States

19 years

2015

26

PROFIT X PRICE ZYNE

Financial Results ZYNE

ZYNE cash flow

Asset, Revenue and Profit Growth - ZYNE

ZYNE balance sheet

CVS - CVS Health

CI - Cigna

CNC - Centene

HUM - Humana

SNY - Sanofi

LLY - Eli Lilly

HCA - HCA Healthcare

NVS - Novartis

CVS - CVS Health

CI - Cigna

CNC - Centene

HUM - Humana

SNY - Sanofi

LLY - Eli Lilly

HCA - HCA Healthcare

NVS - Novartis

Frequently Asked Questions